<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00708578</url>
  </required_header>
  <id_info>
    <org_study_id>LANTU_L_02670</org_study_id>
    <nct_id>NCT00708578</nct_id>
  </id_info>
  <brief_title>Optimal Oral Hypoglycaemic Agents (OHA) for Combination With Insulin Glargine (Sulfonylurea vs. Metformin)</brief_title>
  <official_title>Insulin Glargine Combined With Sulfonylurea Versus Metformin in Patients With Type 2 Diabetes: A Randomized, Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary objective:

      To find out an optimal regimen of OHA (oral hypoglycaemic agents) in combination with insulin
      glargine (metformin, glimepiride or metformin+glimepiride) by measuring HbA1c level

      Secondary objective:

      To compare the incidence of hypoglycemia in each treatment group
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HbA1c values</measure>
    <time_frame>At baseline to end of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hypoglycemia events</measure>
    <time_frame>From inclusion to end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with HbA1c &lt; 7%</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting Blood Glucose level</measure>
    <time_frame>At the end of the study</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">99</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of 4 mg of Glimepiride with Insulin Glargine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of 1500 mg of Metformin with Insulin Glargine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of a combination of 4mg Glimepiride plus 1000mg Metformin with Insulin Glargine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glimepiride</intervention_name>
    <description>Once a day before breakfast</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>After breakfast and supper</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Injection in the morning</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 diabetes for at least 6 months

          -  Treated with maximal, tolerable dose of metformin (≥ 1000mg/day) and sulfonylurea
             (glimepiride≥ 4 mg/day or equivalent dose of other SU) for at least 3 months prior to
             the screening visit

          -  7.0 &lt; HbA1c &lt; 11 %

          -  Fasting serum C-peptide &gt; 0.33 nmol/L

          -  BMI &lt; 30 kg/m²

          -  Patients who is willing to monitor BG using SMBG

        Exclusion Criteria:

          -  Type 1 Diabetes

          -  Clinical evidence of active liver disease, or serum ALT 3 times the upper limit of the
             normal range

          -  Serum creatinine: ≥ 1.5 mg/dl for males, ≥ 1.4 mg/dl for females

          -  Active proliferative diabetic retinopathy, as defined by the application of
             photocoagulation or surgery, in the 6 months before study entry or any other unstable
             (rapidly progressing) retinopathy that may require photocoagulation or surgery during
             the study (an optic fundus examination should have been performed in the 2 years prior
             to study entry)

          -  History of alcohol or other substance abuse

          -  Pregnancy or not using contraceptive in childbearing aged women

          -  Breast feeding women

          -  History of hypersensitivity to the study drugs or to drugs with a similar chemical
             structure

          -  Treatment with any medication including corticosteroid or herbal medicines that can
             affect blood glucose level within 3 months prior to study entry except metformin and
             sulfonylurea.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ji Young Ahn</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-Aventis Administrative Office</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2008</study_first_submitted>
  <study_first_submitted_qc>June 27, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2008</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>Sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Glimepiride</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

